Ionizable lipids for delivery of therapeutic agents and their uses

By developing ionizable lipid nanoparticles, the problems of poor stability and high cost of existing gene therapy vectors in vitro are solved, and efficient and safe delivery of nucleic acids is achieved, which is suitable for the treatment of various genetic defects.

CN117384055BActive Publication Date: 2024-11-19RINUAGENE BIOTECHNOLOGY CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202311329410.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2023-04-27
Filing Date
2023-10-13
Publication Date
2024-11-19
Estimated Expiration
2043-10-13

AI Technical Summary

Technical Problem

Existing gene therapy vectors such as viral vectors, due to their immunogenicity, limited loading and high price, non-viral vectors such as lipid nanoparticles have poor stability in vitro, making it difficult to effectively deliver nucleic acids to target cells.

Method used

A lipid nanoparticle (LNP) containing ionizable lipids has been developed to improve its stability and delivery efficiency in vivo by combining specific construction protocols and targeted ligand modifications for the encapsulation and delivery of nucleic acids.

Benefits of technology

It realizes efficient and safe delivery of nucleic acids into cells, improves the effectiveness of gene therapy, and reduces costs, and is suitable for the treatment of congenital and acquired genetic defects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117384055B_ABST
    Figure CN117384055B_ABST
Patent Text Reader

Abstract

The present disclosure relates to ionizable lipid compounds of formula I, lipid nanoparticles containing the same, and methods for preparing and using the same, wherein each variable is as defined in the specification. #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present disclosure relates to ionizable lipid compounds of formula I, lipid nanoparticles containing the same, and methods for their preparation and use. Background Art

[0002] The effective and targeted delivery of bioactive substances such as small molecule drugs, proteins and nucleic acids is an ongoing medical challenge. The key to the success of gene therapy is whether the therapeutic drugs can be safely and effectively delivered into the target cells through the carrier in vivo. Due to the relative instability of nucleic acids and the low cell permeability of such substances, the delivery of nucleic acids to cells becomes difficult. Therefore, it is necessary to develop methods and compositions to promote the delivery of therapeutic and / or preventive drugs such as nucleic acids to cells. Gene therapy vectors are divided into viral vectors and non-viral vectors. Although viral vectors are used as efficient delivery systems to achieve target gene transfection and treatment purposes, viral vectors contain immunogenic viral proteins, limited target gene loading capacity and high prices. As a non-viral carrier, lipid nanoparticles (LNPs) have received widespread attention due to their good in vitro stability, degradability in vivo, safety and reliability, and are widely used in gene therapy research for congenital and acquired genetic defects.

[0003] Lipid-containing nanoparticles or lipid nanoparticles, liposomes and lipid complexes have been shown to be effective transport carriers for bioactive substances such as small molecule drugs, proteins and nucleic acids entering and / or inside cells. LNPs refer to small vesicles formed by one or more lipid components, which can effectively compress and deliver various nucleic acid molecules, from DNA, RNA to chromosomes and even cells; LNPs are conducive to large-scale production due to their defined construction scheme and easy modification of targeting ligands.

[0004] LNPs generally include one or more cationic lipids and / or amino (ionizable) lipids, phospholipids containing polyunsaturated lipids, structural lipids (such as sterols) and / or lipids containing polyethylene glycol (PEG lipids). For example, patent document WO2017049245A2 discloses a compound and composition for intracellular delivery of therapeutic agents.

[0005] Brief description of the present disclosure

[0006] The present disclosure provides compounds of formula I:

[0007]

[0008] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein each variable is as defined herein.

[0009] The above-mentioned compounds and the general formulae and specific compounds disclosed in the context of the present disclosure, as well as pharmaceutically acceptable salts or stereoisomers thereof, are referred to herein as "compounds of the present disclosure".

[0010] The present disclosure also provides lipid particles, particularly lipid nanoparticles (LNPs), comprising a carrier comprising a compound of the present disclosure and one or more therapeutic and / or prophylactic agents.

[0011] The present disclosure also provides use of the compounds of the present disclosure in preparing medicaments.

[0012] The present disclosure also provides for the use of the compounds of the present disclosure for delivering a therapeutic and / or prophylactic agent to a subject.

[0013] The present disclosure also provides a pharmaceutical composition comprising lipid particles and a pharmaceutically acceptable excipient.

[0014] The present disclosure also provides a method of delivering a therapeutic and / or prophylactic agent to an individual, the method comprising administering the lipid particle or pharmaceutical composition to an individual in need thereof.

[0015] The present disclosure also provides a method for treating or preventing a disease or disorder, comprising administering an effective amount of the lipid particle or pharmaceutical composition to an individual in need thereof.

[0016] The present disclosure also provides a method of introducing a nucleic acid into a cell, the method comprising contacting the cell with the lipid particle or the pharmaceutical composition.

[0017] The present disclosure also provides use of the lipid particles or pharmaceutical compositions for delivering therapeutic and / or prophylactic agents to an individual.

[0018] The present disclosure also provides use of the lipid particle or pharmaceutical composition for treating or preventing a disease or disorder.

[0019] The present disclosure also provides use of the lipid particle or pharmaceutical composition for introducing nucleic acid into cells.

[0020] The present disclosure also provides the lipid particle or pharmaceutical composition for use as a medicament.

[0021] The present disclosure also provides the lipid particles or pharmaceutical compositions for use in delivering therapeutic and / or prophylactic agents to an individual.

[0022] The present disclosure also provides the lipid particle or pharmaceutical composition for use in treating or preventing a disease or disorder.

[0023] The present disclosure also provides the lipid particle or pharmaceutical composition, which is used for introducing nucleic acid into cells.

[0024] The present disclosure also provides use of the lipid particles or pharmaceutical compositions in the preparation of a medicament for delivering a therapeutic and / or preventive agent to an individual.

[0025] The present disclosure also provides use of the lipid particle or pharmaceutical composition in preparing a drug for treating or preventing a disease or condition.

[0026] The present disclosure also provides use of the lipid particle or pharmaceutical composition in preparing a product for introducing nucleic acid into cells. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 Luciferase fluorescence intensity displayed by different LNP formulations in cell transfection experiments.

[0028] Detailed description of the disclosure

[0029] definition

[0030] The following words, phrases and symbols used in this disclosure have the meanings described below, unless otherwise indicated in the context in which they are used. Technical and scientific terms used herein that are not specifically defined have the meanings that are commonly understood by one of ordinary skill in the art to which this disclosure belongs.

[0031] As used herein, "comprising" or "including" is intended to indicate the presence of the features, components or steps mentioned, but they do not exclude the presence or addition of one or more other features, components or steps. Unless otherwise specified, "comprising" or "including" as used herein covers the situation consisting of the features, components or steps mentioned.

[0032] When “and / or” is used to connect two or more optional items, it should be understood as any one of the optional items or a combination of any two or more of the optional items.

[0033] As used herein, "alkyl" refers to a group having 1 to 22 carbon atoms (C 1-22 ), 6-22 carbon atoms (C 6-22 ), 6-20 carbon atoms (C 6-20 ), 6-18 carbon atoms (C 6-18 ), 6-16 carbon atoms (C 6-16 ), 6-12 carbon atoms (C 6-12 ), 8-12 carbon atoms (C 8-12 ), 5-9 carbon atoms (C 5-9 ), 6-8 carbon atoms (C 6-8 ), 2-10 carbon atoms (C 2-10 ), 2-8 carbon atoms (C 2-8 ), 1-6 carbon atoms (C 1-6), 1-4 carbon atoms (C 1-4 ) or 1-3 carbon atoms (C 1-3 ) is a straight-chain or branched saturated hydrocarbon group, such as a straight-chain hydrocarbon group. When the term "alkyl" is prefixed with "C", it indicates the number of carbon atoms. m-n Alkyl means an alkyl group having mn carbon atoms. For example, "C 6-8 "Alkyl" means a straight or branched chain alkyl group having 6, 7 or 8 carbon atoms. 1-6 "Alkyl" means a straight or branched chain alkyl group having 1, 2, 3, 4, 5 or 6 carbon atoms. 6-22 Examples of alkyl groups include, but are not limited to, C 6-18 Straight or branched alkyl, C 8-12 Straight or branched chain alkyl or C 6-12 Straight chain or branched chain alkyl, or C6, C7, C8, C9, C10, C11, ... C20 or C21 straight chain alkyl. 1-6 Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl (e.g., n-propyl, isopropyl), butyl (e.g., n-butyl, isobutyl, sec-butyl, and tert-butyl), pentyl (e.g., n-pentyl, isopentyl, neopentyl), hexyl, and the like.

[0034] As used herein, "alkenyl" refers to a group having 2 to 22 carbon atoms (C 2-22 ), 6-22 carbon atoms (C 6-22 ), 6-20 carbon atoms (C 6-20 ), 6-18 carbon atoms (C 6-18 ), 6-16 carbon atoms (C 6-16 ), 6-12 carbon atoms (C 6-12 ), 8-12 carbon atoms (C 8-12 ), 5-9 carbon atoms (C 5-9 ), 6-8 carbon atoms (C 6-8 ), 2-6 carbon atoms (C 2-6 ), 2-4 carbon atoms (C 2-4 ) or 2-3 carbon atoms (C 2-3 ) is a straight or branched unsaturated hydrocarbon group. 6-22 Examples of alkenyl groups include, but are not limited to, C 6-18 Straight or branched alkenyl, C 8-12 Straight or branched alkenyl or C 6-12 Straight-chain or branched alkenyl, or C6, C7, C8, ... C20 or C21 straight-chain alkenyl.

[0035] As used herein, "alkylene" refers to a divalent radical of an alkyl group as defined herein. Examples of alkylene include straight or branched chain C 1-10 Alkylene, C2-10 Alkylene, C 2-8 Alkylene (e.g. -(CH2) 2-8 -, -(CH2)5-, -(CH2)6-, -(CH2)7-), C 5-8 Alkylene (e.g. -(CH2) 5-8 -), C 1-6 Alkylene (e.g. -(CH2) 1-6 -).

[0036] As used herein, "heteroaryl" refers to a mono- or bicyclic ring system having 5-10 (5-10 members), such as 5-9 (5-9 members), such as 5-6 (5-6 members) or 8-9 (8-9 members), ring atoms, which contains at least 1 nitrogen heteroatom, wherein at least one ring is an aromatic ring containing heteroatoms. For example, the ring atoms include one or more, such as 1, 2, 3 or 4, preferably 1, 2 or 3 heteroatoms independently selected from N, O and S (preferably N), and at least one heteroatom is N, and the remaining ring atoms are carbon atoms. When the total number of S and O atoms in the heteroaryl exceeds 1, these S and O heteroatoms are not adjacent to each other. For example, the heteroaryl includes, but is not limited to:

[0037] 5-6 membered monocyclic heteroaryl, i.e., a monocyclic aromatic hydrocarbon group having 5 or 6 ring atoms, wherein the ring atoms include one or more, for example 1, 2 or 3, heteroatoms independently selected from N, O and S (preferably N), and at least one heteroatom is N, and the remaining ring atoms are carbon atoms; for example, the ring atoms include 1, 2 or 3 N heteroatoms, and the remaining ring atoms are carbon atoms. The heteroaryl is, for example, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrazinyl, pyrimidinyl, isoxazolyl, triazinyl, oxazolyl, thiadiazolyl, pyridazinyl, preferably imidazolyl, such as imidazol-4-yl; and

[0038] 8-10 membered bicyclic heteroaryl, i.e., a bicyclic aromatic hydrocarbon group having 8, 9 or 10 ring atoms, wherein the ring atoms include one or more, such as 1, 2, 3 or 4, preferably 1, 2 or 3, heteroatoms independently selected from N, O and S (preferably N), and at least one heteroatom is N, and the remaining ring atoms are carbon atoms, wherein at least one ring is an aromatic ring; for example, the ring atoms include 1, 2 or 3 N heteroatoms, and the remaining ring atoms are carbon atoms. The heteroaryl is, for example, an 8-9 membered bicyclic heteroaryl, such as indolyl, indol-3-yl.

[0039] As used herein, "-OH" refers to a hydroxyl group.

[0040] As used herein, "optional", "optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where the event or circumstance occurs as well as instances where the event or circumstance does not occur. For example, "optionally substituted with" includes unsubstituted and substituted with 1, 2, 3 or more of the described substituents. It will be understood by those skilled in the art that for any group containing one or more substituents, the group does not include any sterically impractical, chemically incorrect, synthetically infeasible and / or inherently unstable substitution patterns.

[0041] It will be appreciated by those skilled in the art that compounds of formula I may contain one or more chiral centers, and therefore there are two or more stereoisomers. Racemic mixtures of these isomers, single isomers, and mixtures enriched in one enantiomer, as well as diastereomers when there are two chiral centers, and mixtures partially enriched in specific diastereomers are all within the scope of the present disclosure. It will also be appreciated by those skilled in the art that the present disclosure includes all single stereoisomers (e.g., enantiomers), racemic mixtures, or partially resolved mixtures of compounds of formula I, and, where appropriate, includes its single tautomers.

[0042] As used herein, "pharmaceutically acceptable salts" refer to salts of free acids or bases of compounds of formula (I) that are non-toxic, biologically tolerable, or otherwise biologically suitable for administration to treat or prevent an individual. For example, acid addition salts include, for example, addition salts derived from inorganic acids and organic acids, the inorganic acids including, for example, hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and nitric acid, the organic acids including, for example, p-toluenesulfonic acid, salicylic acid, methanesulfonic acid, oxalic acid, succinic acid, citric acid, malic acid, lactic acid, fumaric acid, etc. For a general description of pharmaceutically acceptable salts, see, for example, SM Berge et al., "Pharmaceutical Salts", J. Pharm. Sci., 1977, 66: 1-19, and Handbook of Pharmaceutical Salts, Properties, Selection, and Use, Stahl and Wermuth, ed., Wiley-VCH and VHCA, Zurich, 2002.

[0043] As used herein, "pharmaceutically acceptable excipients" refer to excipients that are compatible with the active ingredient or lipid particles in the composition (in some embodiments, can stabilize the active ingredient) and are not harmful to the individual being treated. Suitable pharmaceutically acceptable excipients are disclosed in the standard reference book in the field (Remington's Pharmaceutical Sciences).

[0044] As used herein, "delivery" means providing an entity to a target. For example, delivering a therapeutic and / or prophylactic agent to an individual may involve administering lipid nanoparticles comprising the therapeutic and / or prophylactic agent to the individual (e.g., via intravenous, intramuscular, intradermal, or subcutaneous routes). Administering lipid nanoparticles to a mammal or mammalian cell may involve contacting one or more cells with a nanoparticle composition.

[0045] As used herein, "therapeutic and / or prophylactic agent", "therapeutic agent" or "prophylactic agent" refers to any agent that has a therapeutic, diagnostic and / or prophylactic effect and / or causes a desired biological and / or pharmacological effect when administered to a subject. Therapeutic and / or prophylactic agents are also referred to as "active substances" or "active agents". Such agents include, but are not limited to, cytotoxins, radioactive ions, chemotherapeutic agents, small molecule drugs, proteins and nucleic acids. For example, the therapeutic and / or prophylactic agent is a vaccine, a compound that elicits an immune response (e.g., a polynucleotide or nucleic acid molecule encoding a protein or polypeptide or peptide), and / or another therapeutic and / or prophylactic agent. Vaccines include compounds and preparations that can provide immunity to one or more diseases associated with infectious diseases, and may include mRNA encoding antigens and / or epitopes derived from infectious diseases. Vaccines also include compounds and preparations that direct an immune response against cancer cells, and may include mRNA encoding antigens, epitopes and / or neo-epitopes derived from tumor cells. For example, a vaccine and / or a compound that can elicit an immune response is administered intramuscularly via the composition of the present disclosure. For example, the therapeutic and / or preventive agent is a protein, such as a protein required to enhance or replace a naturally occurring protein of interest. Such proteins or polypeptides may be naturally occurring, or may be modified using methods known in the art, such as to increase half-life. Exemplary proteins are intracellular, transmembrane, or secreted.

[0046] Preferably, the treatment and / or preventive agent is selected from ribonucleic acid (RNA) and deoxyribonucleic acid (DNA), such as natural or modified RNA or DNA. For example, the RNA is selected from single-stranded RNA, double-stranded RNA (dsRNA), partially double-stranded RNA and mixtures thereof, and / or the RNA is selected from circular RNA, linear RNA and mixtures thereof. The treatment and / or preventive agent includes, but is not limited to, messenger RNA (mRNA), short interfering RNA (siRNA), asymmetric interfering RNA (aiRNA), RNA interference (RNAi) molecules, microRNA (miRNA), antisense RNA, ribozymes, Dicer-substrate RNA (dsRNA), small hairpin RNA (shRNA) and mixtures thereof. mRNA, for example, includes one or more of a stem loop, a chain terminating nucleoside, a poly A sequence, a polyadenylation signal and / or a 5' cap structure. mRNA may include one or more modified nucleobases, nucleosides or nucleotides, in which case it may be referred to as "modified mRNA" or "mmRNA".

[0047] The DNA molecule can be a double-stranded DNA, a single-stranded DNA (ssDNA) or a molecule that is partially double-stranded DNA, i.e., has a portion that is double-stranded and a portion that is single-stranded. The DNA molecule can be triple-stranded or partially triple-stranded, i.e., has a portion that is triple-stranded and a portion that is double-stranded. The DNA molecule can be a circular DNA molecule or a linear DNA molecule. The DNA treatment and / or preventive can be a DNA molecule that can transfer a gene into a cell, such as one that encodes and can express a transcript. In other embodiments, the DNA molecule is a synthetic molecule, such as a synthetic DNA molecule produced in vitro. For example, the DNA molecule is a recombinant molecule. Non-limiting examples of DNA treatments and / or preventives include plasmid expression vectors and viral expression vectors.

[0048] As used herein, an "effective amount" refers to an amount of a therapeutic and / or prophylactic agent (e.g., a nucleic acid, a drug, a composition, a therapeutic agent, a diagnostic agent, a prophylactic agent, etc.) to be delivered that is sufficient to produce a beneficial effect, and when administered to an individual suffering from or susceptible to an infection, disease, and / or condition, the amount is sufficient to treat the infection, disease, and / or condition, alleviate, relieve, ameliorate its symptoms, inhibit its progression, reduce its severity, diagnose, prevent, and / or delay its onset.

[0049] " entrapment efficiency " used herein refers to the amount of the treatment and / or preventive agent that becomes the part of lipid particle composition relative to the initial total amount of the treatment and / or preventive agent used in lipid particle preparation.For example, if 97mg treatment and / or preventive agent are encapsulated in lipid particle in the 100mg treatment and / or preventive agent initially provided for compositions, then can provide entrapment efficiency of 97%.

[0050] As used herein, "polydispersity index" or "PDI" is a ratio that describes the uniformity of the particle size distribution of a system. Small values ​​(eg, less than 0.3) indicate a narrow particle size distribution.

[0051] "Lipid particle" used herein is a composition comprising one or more lipids and one or more therapeutic and / or preventive agents. The size of lipid particles is generally micron-sized or smaller, and may include a lipid bilayer. Lipid particles include lipid nanoparticles (LNP), liposomes (e.g., lipid vesicles) and cationic liposome complexes (lipoplex), preferably lipid nanoparticles. Lipid nanoparticles are spherical or polyhedral particles of nanometer (1-1000nm) size, with electron-dense cores, and due to the presence of ionizable lipids, LNPs can be negatively charged nucleic acids encapsulated in the core of particles by mutual adsorption of positive and negative charges. For example, the diameter of the lipid nanoparticle group is about 50-500nm, for example, about 50-350nM. Therapeutic or preventive agents, such as nucleic acids, can be encapsulated in the lipid portion of lipid nanoparticles or in the aqueous space encapsulated by some or all of the lipid portions of lipid nanoparticles, thereby protecting them from enzymatic degradation or other undesirable effects such as adverse immune responses induced by the mechanism of host organisms or cells.

[0052] As used herein, "ionizable lipids" refer to lipids that are ionizable, such that they can exist in a positively charged or neutral form depending on pH. The compounds disclosed herein are ionizable lipids. Under different pH conditions, the ionization of ionizable lipids affects the surface charge of lipid nanoparticles.

[0053] As used herein, "phospholipids" are lipids that include a phosphate moiety and one or more carbon chains, such as unsaturated fatty acid chains. Phospholipids may include one or more multiple (e.g., double or triple) bonds (e.g., one or more degrees of unsaturation). Specific phospholipids may promote fusion with membranes. Fusion of phospholipids with membranes may allow lipid-containing compositions to pass through the membrane, thereby allowing, for example, one or more components to be delivered to cells.

[0054] The phospholipids include, but are not limited to, phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidic acid, palmitoyloleylphosphatidylcholine, lysophosphatidylcholine, and lysophosphatidylethanolamine (LPE). For example, the phospholipid is selected from: 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-glycero-phosphocholine (DMPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-di-undecanoyl-sn-glycero-phosphocholine (DUPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 diether PC), 1-oleoyl-2-cholesteryl hemisuccinyl-sn-glycero-3-phosphocholine (OChemsPC), 1-hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC), 1,2-dilinoleoyl-sn-glycero-3-phosphocholine, 1,2-arachidonoyl-sn-glycero-3-phosphocholine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (ME 16.0PE), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine, 1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine, 1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt (DOPG), dipalmitoylphosphatidylglycerol (DPPG), palmitoyloleoylphosphatidylethanolamine (POPE), distearoyl-phosphatidyl-ethanolamine (DSPE), dipalmitoylphosphatidylethanolamine (DPPE), dimyristoylphosphoethanolamine (DMPE), 1-stearoyl-2-oleoyl-phosphatidylethanolamine (SOPE), 1-stearoyl-2-oleoyl-phosphatidylcholine (SOPC), sphingomyelin and mixtures thereof. The phospholipid is preferably 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) or a combination thereof.

[0055] "PEG lipid" or "PEGylated lipid" as used herein refers to a lipid molecule comprising a polyethylene glycol portion or a lipid modified with polyethylene glycol. The PEG lipid includes, but is not limited to, PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol, and PEG-modified dialkylglycerol and mixtures thereof. For example, the PEG lipid is selected from 1,2-dimyristoyl-sn-glyceromethoxypolyethylene glycol (PEG-DMG), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino (polyethylene glycol)] (PEG-DSPE), PEG-distearyl glycerol (PEG-DSG), PEG-dipalmitoyl, PEG-dioleyl, PEG-distearyl, PEG-diacyl glycinamide (PEG-DAG), PEG-dipalmitoyl phosphatidylethanolamine (PEG-DPPE) or PEG-l,2-dimyristoyloxypropyl-3-amine (PEG-c-DMA). The PEG lipid is preferably 1,2-dimyristoyl-sn-glyceromethoxypolyethylene glycol (PEG-DMG) or 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)] (PEG-DSPE), such as 1,2-dimyristoyl-sn-glyceromethoxypolyethylene glycol 2000 (PEG 2k -DMG) or 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol 2000)](PEG 2k -DSPE).

[0056] As used herein, "steroids" are also referred to as sterols, which include, but are not limited to, cholesterol, fecosterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, and mixtures thereof.

[0057] As used herein, "administering" refers to physically introducing one or more therapeutic and / or preventive agents into an individual using a variety of methods known to those skilled in the art and a delivery system of the present disclosure, such as LNP. The administration routes disclosed herein include oral, intravenous (e.g., infusion, infusion or injection), intramuscular, subcutaneous, intradermal, intraperitoneal, spinal, topical or other parenteral administration routes. As used herein, the phrase "parenteral administration" refers to administration methods other than gastrointestinal and topical administration, usually intravenously, and includes, but is not limited to, intramuscular, intraarterial, intrathecal, intralymphatic, intralesional, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcutaneous, intraarticular, subcapsular, subarachnoid, intraspinal, epidural and intrasternal injection and infusion, and in vivo electroporation. Accordingly, each active agent in the combination of the present disclosure can be formulated into capsules, tablets, injections (including infusions or injections), syrups, sprays, lozenges, liposomes or suppositories, etc.

[0058] As used herein, "individual" or "patient" refers to mammals and non-mammals. Mammals refer to any member of the mammal class, including but not limited to: humans; non-human primates, cattle, horses, sheep, pigs, rabbits, dogs and cats, etc. "Individual" is not limited to a specific age or gender. Preferably, the individual or patient is a human.

[0059] The term "about" means within ±20% of a given value or range, such as within ±10%, within ±5%.

[0060] All numerical ranges herein should be understood to disclose every value and subset of values ​​within the range, regardless of whether they are specifically disclosed otherwise. For example, when any numerical range is mentioned, it should be considered to mention every value within the numerical range, such as every integer within the numerical range, such as C in this article. 1-6 Meaning includes 1, 2, 3, 4, 5 or 6 C. The present disclosure is contemplated by all values ​​falling within these ranges, all smaller ranges and upper or lower limits of numerical ranges. DETAILED DESCRIPTION

[0061] Embodiment 1. Compound of formula I,

[0062]

[0063] or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

[0064] R1 and R2 are each independently a linear or branched C 6-22 Alkyl or C 6-22 alkenyl;

[0065] R3 is H, straight or branched C 1-6 Alkyl, or -L3-G3-R3', wherein R3' is a linear or branched C 6-22 Alkyl or C 6-22 alkenyl;

[0066] R4 is -C 1-6 Alkylene-NR'R", 5-10 membered heteroaryl, phenyl-OH or -OH, wherein the heteroaryl contains at least 1 nitrogen heteroatom and is optionally substituted by 1, 2 or 3 C 1-6 Alkyl or C 1-6 Alkyl-OH substituted; wherein R' and R" are each independently H or C 1-3 alkyl;

[0067] R5 is H or straight or branched C 1-6 alkyl;

[0068] L1, L2 and L3 are each independently a linear or branched C 2-10 Alkylene;

[0069] G1, G2 and G3 are each independently -O(C=O)- or -(C=O)O-; and

[0070] n is 0 or 1.

[0071] Embodiment 2. The compound according to Embodiment 1, its pharmaceutically acceptable salt or stereoisomer, wherein the compound has the structure of Formula Ia:

[0072]

[0073] Embodiment 3. The compound according to Embodiment 1, a pharmaceutically acceptable salt or a stereoisomer thereof, wherein the compound has the structure of Formula Ib:

[0074]

[0075] Embodiment 4. A compound according to any one of the preceding embodiments, a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R3′ is a linear or branched C 6-18 alkyl.

[0076] Embodiment 5. A compound according to any one of the preceding embodiments, a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R3′ is a linear C 8-12 Alkyl, -(CH2) substituted with 1 or 2 methyl or ethyl groups 7-11 -CH3, -CHRaRb, or -CH2CHRaRb, wherein Ra and Rb are each independently a linear C 6-12 Alkyl, preferably straight chain C 6-8 alkyl.

[0077] Embodiment 6. A compound according to any one of the preceding embodiments, a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R3′ is a linear C 8-12 Alkyl, -(CH2) 6-10 -isopropyl or -CHRaRb, wherein Ra and Rb are each independently a straight chain C7- 10 Alkyl, preferably straight chain C 6-8 alkyl.

[0078] Embodiment 7. A compound according to any one of the preceding embodiments, a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R4 is -C 1-6 Alkylene-NR'R", 5-9 membered heteroaryl, phenyl-OH or -OH, wherein the heteroaryl contains at least 1 nitrogen heteroatom and is optionally substituted by 1, 2 or 3 C 1-6 Alkyl or C 1-6 Alkyl-OH substituted; wherein R' and R" are H or C 1-3 alkyl.

[0079] Embodiment 8. A compound according to any one of the preceding embodiments, a pharmaceutically acceptable salt or a stereoisomer thereof, wherein L1, L2 and L3 are each independently a linear C 2-8 Alkylene.

[0080] Embodiment 9. A compound according to any one of the preceding embodiments, a pharmaceutically acceptable salt or a stereoisomer thereof, wherein G1 is -O(C=O)-; and G2 and G3 are each -(C=O)O-.

[0081] Embodiment 10. A compound according to any one of the preceding embodiments, a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R2 is -CHRaRb, wherein Ra and Rb are each independently a linear C 6-12 Alkyl, preferably straight chain C 6-8 alkyl; R3 is H; R4 is -OH; and R5 is H.

[0082] Embodiment 11. The compound according to Embodiment 1, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein:

[0083] R1 and R2 are each independently a linear or branched C 6-22 Alkyl or C 6-22 alkenyl;

[0084] R3 is H or straight or branched C 1-6 alkyl;

[0085] R4 is -C 1-6 Alkylene-NR'R" or 5-10 membered heteroaryl, the heteroaryl containing at least 1 nitrogen heteroatom and optionally 1, 2 or 3 C 1-6 Alkyl or C 1-6 Alkyl-OH substituted; wherein R' and R" are each independently H or C 1-3 alkyl;

[0086] R5 is H;

[0087] L1 and L2 are each independently a linear or branched C 2-10 Alkylene;

[0088] G1 and G2 are each independently -O(C=O)- or -(C=O)O-; and

[0089] n is 0 or 1.

[0090] Embodiment 12. A compound according to any one of the preceding embodiments, a pharmaceutically acceptable salt or a stereoisomer thereof, wherein L1 and L2 are each independently a linear C 2-8 Alkylene, preferably straight chain C 2-6 Alkylene.

[0091] Embodiment 13. A compound according to any one of the preceding embodiments, a pharmaceutically acceptable salt or a stereoisomer thereof, wherein L1 and L2 are each independently -(CH2) 2-8 -, which is optionally substituted by 1 or 2 methyl or ethyl groups.

[0092] Embodiment 14. A compound according to any one of the preceding embodiments, a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R1 is a linear or branched C 6-18 Alkyl groups, such as straight chain C 8-12 alkyl.

[0093] Embodiment 15. A compound according to any one of the preceding embodiments, a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R2 is a linear or branched C 6-18 Alkyl groups, such as straight chain C 8-12 alkyl.

[0094] Embodiment 16. A compound according to any one of the preceding embodiments, a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R2 is a linear C 6-18 Alkyl, -(CH2) substituted with 1 or 2 methyl or ethyl groups 7-11 -CH3, -CHRaRb or -CH2CHRaRb, wherein Ra and Rb are each independently a straight chain C 6-12 Alkyl, preferably straight chain C 6-8 alkyl.

[0095] Embodiment 17. A compound according to any one of the preceding embodiments, a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R2 is a linear C 8-12 Alkyl, -(CH2) 6-10 -isopropyl or -CHRaRb, wherein Ra and Rb are each independently a straight chain C7- 10 alkyl.

[0096] Embodiment 18. A compound according to any one of the preceding embodiments, a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R3 is H, methyl or ethyl; preferably R3 is H or methyl.

[0097] Embodiment 19. A compound according to any one of the preceding embodiments, a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R4 is -C 1-6 Alkylene-NR'R" or 5-9 membered heteroaryl containing 1, 2 or 3 nitrogen heteroatoms and optionally 1, 2 or 3 C 1-6 Alkyl or C 1-6 Alkyl-OH substituted; wherein R' and R" are each independently H or C 1-3 alkyl.

[0098] Embodiment 20. A compound according to any one of the preceding embodiments, a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R4 is -C 1-6 Alkylene-NR'R" or 5-6 membered heteroaryl containing 1, 2 or 3 nitrogen heteroatoms and optionally 1 or 2 C 1-6 Alkyl-OH substituted; wherein R' and R" are each independently H or C 1-3 alkyl.

[0099] Embodiment 21. A compound according to any one of the preceding embodiments, a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R4 is -C 1-6 Alkylene-NR'R" or 5-membered heteroaryl, the heteroaryl containing 1 or 2 nitrogen heteroatoms and optionally 1 or 2 C 1-3 wherein R' and R" are each independently H or methyl.

[0100] Embodiment 22. A compound according to any one of the preceding embodiments, a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R4 is -(CH2)3-NR'R" or is optionally substituted by 1 C 1-3 Alkyl-OH substituted imidazolyl, wherein R' and R" are each independently H or methyl.

[0101] Embodiment 23. A compound according to any one of the preceding embodiments, a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R4 is -(CH2)3-NR'R", wherein R' and R" are each independently H or C 1-3 alkyl.

[0102] Embodiment 24. A compound according to any one of the preceding embodiments, a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R4 is optionally replaced by 1 C 1-3 Alkyl-OH substituted imidazolyl or indolyl, for example or R4 is optionally replaced by 1 C 1-3 Alkyl-OH substituted imidazole, such as

[0103] Embodiment 25. A compound according to any one of the preceding embodiments, a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R4 is -(CH2)3-NR'R", R' and R" are each independently H or methyl.

[0104] Embodiment 26. A compound according to any one of the preceding embodiments, a pharmaceutically acceptable salt or a stereoisomer thereof, wherein

[0105] R1 is a straight chain C8-12 alkyl;

[0106] R2 is a straight chain C 8-12 Alkyl, -(CH2) 6-10 -isopropyl or -CHRaRb, wherein Ra and Rb are each independently a straight chain C 7-10 alkyl;

[0107] R3 is H or methyl;

[0108] R4 is -(CH2)3-NR'R", wherein R' and R" are each independently H or methyl;

[0109] R5 is H;

[0110] L1 and L2 are each independently a linear C 2-6 Alkylene;

[0111] G1 and G2 are each independently -O(C=O)- or -(C=O)O-; and

[0112] n is 0 or 1.

[0113] Embodiment 27. A compound according to any one of the preceding embodiments, a pharmaceutically acceptable salt or a stereoisomer thereof, wherein n is 0.

[0114] Embodiment 28. A compound according to any one of the preceding embodiments, a pharmaceutically acceptable salt or a stereoisomer thereof, wherein n is 1.

[0115] Embodiment 29. A compound according to any one of the preceding embodiments, a pharmaceutically acceptable salt or a stereoisomer thereof, wherein G1 and G2 are different or the same.

[0116] Embodiment 30. A compound according to any one of the preceding embodiments, a pharmaceutically acceptable salt or a stereoisomer thereof, wherein G1 is -O(C=O)-.

[0117] Embodiment 31. A compound according to any one of the preceding embodiments, a pharmaceutically acceptable salt or a stereoisomer thereof, wherein G2 is -(C=O)O-.

[0118] Embodiment 32. A compound according to any one of the preceding embodiments, a pharmaceutically acceptable salt or a stereoisomer thereof, wherein Ra and Rb are the same, for example Ra and Rb are each a linear C8 alkyl group.

[0119] Embodiment 33. A compound according to any one of the preceding embodiments, a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R2 is a linear C 10 Alkyl, straight chain C 12 alkyl,

[0120] Embodiment 34. The compound according to Embodiment 1, its pharmaceutically acceptable salt or stereoisomer, wherein the compound is selected from:

[0121]

[0122]

[0123] Embodiment 35. A lipid particle comprising a carrier and one or more therapeutic and / or preventive agents, wherein the carrier comprises a compound, a pharmaceutically acceptable salt or a stereoisomer thereof as described in any one of the preceding embodiments 1-34, and preferably the lipid particle is a lipid nanoparticle (LNP).

[0124] Embodiment 36. The lipid particle according to the preceding embodiment 35, wherein the one or more therapeutic and / or prophylactic agents are nucleic acids.

[0125] Embodiment 37. A lipid particle according to any one of embodiments 35-36, wherein the one or more therapeutic and / or prophylactic agents are selected from ribonucleic acid (RNA) and deoxyribonucleic acid (DNA), such as natural or modified RNA or DNA.

[0126] Embodiment 38. A lipid particle according to any one of embodiments 35-37, wherein the one or more therapeutic and / or prophylactic agents are RNA, for example, the RNA is selected from single-stranded RNA, double-stranded RNA (dsRNA), partially double-stranded RNA and mixtures thereof, and / or the RNA is selected from circular RNA, linear RNA and mixtures thereof.

[0127] Embodiment 39. A lipid particle according to any one of embodiments 35-38, wherein the one or more therapeutic and / or prophylactic agents are selected from: messenger RNA (mRNA), short interfering RNA (siRNA), asymmetric interfering RNA (aiRNA), RNA interference (RNAi) molecules, micro RNA (miRNA), antisense RNA, ribozymes, Dicer-substrate RNA (dsRNA), small hairpin RNA (shRNA) and mixtures thereof.

[0128] Embodiment 40. The lipid particle according to any one of embodiments 35-39, wherein the one or more therapeutic and / or prophylactic agents is mRNA.

[0129] Embodiment 41. A lipid particle according to any one of embodiments 35-40, wherein the one or more therapeutic and / or prophylactic agents is an mRNA comprising one or more of a stem-loop, a chain-terminating nucleoside, a poly-A sequence, a polyadenylation signal and / or a 5' cap structure.

[0130] Embodiment 42. A lipid particle according to any one of embodiments 35-41, wherein the one or more therapeutic and / or prophylactic agents is a natural or modified mRNA.

[0131] Embodiment 43. A lipid particle according to any one of embodiments 35-37, wherein the one or more therapeutic and / or prophylactic agents is DNA, for example, the DNA is selected from double-stranded DNA, single-stranded DNA (ssDNA), partially double-stranded DNA, triple-stranded DNA and partially triple-stranded DNA, and / or the DNA is selected from circular DNA, linear DNA and mixtures thereof, for example, the DNA is a recombinant molecule, for example, selected from a plasmid expression vector, a viral expression vector and mixtures thereof.

[0132] Embodiment 44. The lipid particle according to any one of embodiments 35-43, wherein the carrier further comprises a phospholipid, a steroid and a PEG lipid.

[0133] Embodiment 45. A lipid particle according to any one of embodiments 35-44, comprising a compound, a pharmaceutically acceptable salt or a stereoisomer thereof according to any one of embodiments 1-34 in an amount of 30 to 60 mol %, for example 40 to 60 mol % or 35 to 55 mol % of the carrier.

[0134] Embodiment 46. The lipid particle according to any one of embodiments 35-45, comprising phospholipids in an amount of 0.5 to 30 mol %, such as 1 to 20 mol % or 5 to 25 mol % of the carrier.

[0135] Embodiment 47. The lipid particle according to any one of embodiments 35-46, comprising the steroid in an amount of 18 to 50 mol %, such as 30 to 45 mol % or 30 to 40 mol % of the carrier.

[0136] Embodiment 48. The lipid particle according to any one of embodiments 35-47, comprising the PEG lipid in an amount of 0.1 to 10 mol %, such as 0.5 to 5 mol %, of the carrier.

[0137] Embodiment 49. A lipid particle according to any one of embodiments 35-48, comprising a compound of any one of embodiments 1-34, a pharmaceutically acceptable salt or stereoisomer thereof in an amount of 40 to 60 mol% of the carrier, a phospholipid in an amount of 1 to 20 mol% of the carrier, a steroid in an amount of 30 to 45 mol% of the carrier, and a PEG lipid in an amount of 0.5 to 5 mol% of the carrier.

[0138] Embodiment 50. A lipid particle according to any one of embodiments 35-49, comprising a compound of any one of embodiments 1-34, a pharmaceutically acceptable salt or stereoisomer thereof in an amount of about 50 mol% of the carrier, a phospholipid in an amount of about 10 mol% of the carrier, a steroid in an amount of about 38.5 mol% of the carrier, and a PEG lipid in an amount of about 1.5 mol% of the carrier.

[0139] Embodiment 51. A lipid particle according to any one of embodiments 46-50, wherein the phospholipid is selected from: phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidic acid, palmitoyloleoylphosphatidylcholine, lysophosphatidylcholine and lysophosphatidylethanolamine (LPE).

[0140] Embodiment 52. A lipid particle according to any one of embodiments 46-51, wherein the phospholipid is selected from: 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-glycero-phosphocholine (DMPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-di- choline (DSPC), 1,2-di-undecanoyl-sn-glycero-phosphocholine (DUPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 diether PC), 1-oleoyl-2-cholesteryl hemisuccinyl-sn-glycero-3-phosphocholine (OChemsPC), 1-hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC), 1,2-dialinolenoyl-sn-glycero-3-phosphocholine, 1,2-diacetyl-sn-glycero-3-phosphocholine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (ME 16.0PE), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinolenoyl-sn-glycero-3-phosphoethanolamine, 1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine, 1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt (DOPG), dipalmitoylphosphatidylglycerol (DPPG), palmitoyloleoylphosphatidylethanolamine (POPE), distearoyl-phosphatidyl-ethanolamine (DSPE), dipalmitoylphosphatidylethanolamine (DPPE), dimyristoylphosphoethanolamine (DMPE), 1-stearoyl-2-oleoyl-phosphatidylethanolamine (SOPE), 1-stearoyl-2-oleoyl-phosphatidylcholine (SOPC), sphingomyelin and mixtures thereof.

[0141] Embodiment 53. The lipid particle according to any one of embodiments 46-52, wherein the phospholipid is 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC).

[0142] Embodiment 54. The lipid particle according to any one of embodiments 47-53, wherein the steroid is selected from cholesterol, coproposterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol and mixtures thereof.

[0143] Embodiment 55. The lipid particle according to any one of embodiments 47-54, wherein the steroid is cholesterol.

[0144] Embodiment 56. A lipid particle according to any one of embodiments 48-55, wherein the PEG lipid is selected from: PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol and PEG-modified dialkylglycerol and mixtures thereof.

[0145] Embodiment 57. A lipid particle according to any one of embodiments 48-56, wherein the PEG lipid is selected from: 1,2-dimyristoyl-sn-glyceromethoxypolyethylene glycol (PEG-DMG), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)] (PEG-DSPE), PEG-distearylglycerol (PEG-DSG), PEG-dipalmitoleyl, PEG-dioleyl, PEG-distearyl, PEG-diacyl glycinamide (PEG-DAG), PEG-dipalmitoylphosphatidylethanolamine (PEG-DPPE) or PEG-l,2-dimyristyloxypropyl-3-amine (PEG-c-DMA).

[0146] Embodiment 58. A lipid particle according to any one of embodiments 48-57, wherein the PEG lipid is 1,2-dimyristoyl-sn-glyceromethoxypolyethylene glycol 2000 (PEG 2k -DMG) or 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol 2000)](PEG 2k -DSPE).

[0147] Embodiment 59. The lipid particle according to any one of embodiments 44-58, wherein the one or more therapeutic and / or prophylactic agents is mRNA, the phospholipid is DSPC, the steroid is cholesterol, and the lipid is PEG-DMG.

[0148] Embodiment 60. The lipid particle according to any one of embodiments 40-59, wherein the weight ratio of the lipid component to the mRNA is 10:1 to 60:1, such as 15:1 to 30:1, such as 20:1.

[0149] Embodiment 61. The lipid particle according to any one of embodiments 35-60, wherein the lipid particle is a lipid nanoparticle (LNP).

[0150] Embodiment 62. A pharmaceutical composition comprising the lipid particle of any one of embodiments 35-61 and a pharmaceutically acceptable excipient.

[0151] Embodiment 63. The pharmaceutical composition according to embodiment 62, wherein the pharmaceutically acceptable excipient is selected from a cryoprotectant, a buffer or a combination thereof.

[0152] Embodiment 64. Use of a compound according to any one of Embodiments 1-34, a pharmaceutically acceptable salt or a stereoisomer thereof in the preparation of a medicament comprising the nucleic acid according to any one of Embodiments 36-43.

[0153] Embodiment 65. Use of a compound according to any one of Embodiments 1-34, a pharmaceutically acceptable salt or stereoisomer thereof for delivering a therapeutic and / or prophylactic agent to a subject, wherein the therapeutic and / or prophylactic agent is a nucleic acid according to any one of Embodiments 36-43.

[0154] Embodiment 66. A method of delivering a therapeutic and / or prophylactic agent to an individual, the method comprising administering to an individual in need thereof the lipid particle of any one of embodiments 35-61 or the pharmaceutical composition of any one of embodiments 62-63.

[0155] Embodiment 67. A method according to embodiment 66, wherein the lipid particle or pharmaceutical composition is administered parenterally, such as intramuscularly, intradermally, subcutaneously and / or intravenously.

[0156] Embodiment 68. A method of treating or preventing a disease or condition, the method comprising administering to an individual in need thereof an effective amount of the lipid particle of any one of embodiments 35-61 or the pharmaceutical composition of any one of embodiments 62-63.

[0157] Embodiment 69. A method according to embodiment 68, wherein the lipid particle or pharmaceutical composition is administered parenterally, such as intramuscularly, intradermally, subcutaneously and / or intravenously.

[0158] Embodiment 70. The method according to embodiment 68 or 69, wherein the disease or condition is selected from infectious diseases, such as viral infections, cancer, liver diseases, autoimmune diseases, diabetes, neurodegenerative diseases, cardiovascular and renal vascular diseases and metabolic diseases.

[0159] Embodiment 71. A method of introducing a nucleic acid into a cell, the method comprising contacting the cell with the lipid particle of any one of embodiments 36-61 or the pharmaceutical composition of any one of embodiments 62-63.

[0160] Embodiment 72. A method according to embodiment 71, wherein the method introduces the nucleic acid into the cell in vitro.

[0161] Embodiment 73. A method according to embodiment 71 or 72, wherein the cell is a mammalian cell.

[0162] Embodiment 74. The lipid particle of any one of embodiments 35-61 or the pharmaceutical composition of any one of embodiments 62-63 for use as a medicament.

[0163] Embodiment 75. The lipid particle of any one of embodiments 35-61 or the pharmaceutical composition of any one of embodiments 62-63, for use in delivering a therapeutic and / or prophylactic agent to a subject.

[0164] Embodiment 76. The lipid particle or pharmaceutical composition for use according to embodiment 75, wherein the lipid particle or pharmaceutical composition is administered parenterally, such as intramuscularly, intradermally, subcutaneously and / or intravenously.

[0165] Embodiment 77. The lipid particle of any one of embodiments 35-61 or the pharmaceutical composition of any one of embodiments 62-63 for use in treating or preventing a disease or disorder in a subject.

[0166] Embodiment 78. The lipid particle or pharmaceutical composition for use according to Embodiment 77, wherein the lipid particle or pharmaceutical composition is administered parenterally, such as intramuscularly, intradermally, subcutaneously and / or intravenously.

[0167] Embodiment 79. The lipid particle or pharmaceutical composition for use according to embodiment 77 or 78, wherein the disease or condition is selected from infectious diseases, such as viral infections, cancer, liver diseases, autoimmune diseases, diabetes, neurodegenerative diseases, cardiovascular and renal vascular diseases, and metabolic diseases.

[0168] Embodiment 80. The lipid particle of any one of embodiments 36-61 or the pharmaceutical composition of any one of embodiments 62-63, for use in introducing a nucleic acid into a cell.

[0169] Embodiment 81. The lipid particle or pharmaceutical composition for use according to embodiment 80, for introducing nucleic acid into cells in vitro.

[0170] Embodiment 82. The lipid particle or pharmaceutical composition for use according to embodiment 80 or 81, wherein the cell is a mammalian cell.

[0171] Embodiment 83. Use of the lipid particle of any one of embodiments 35-61 or the pharmaceutical composition of any one of embodiments 62-63 in the preparation of a medicament for delivering a therapeutic and / or prophylactic agent to an individual.

[0172] Embodiment 84. Use of the lipid particle of any one of embodiments 35-61 or the pharmaceutical composition of any one of embodiments 62-63 in the preparation of a medicament for treating or preventing a disease or disorder in a subject.

[0173] Embodiment 85. The use according to embodiment 84, wherein the disease or condition is selected from infectious diseases, such as viral infections, cancer, liver diseases, autoimmune diseases, diabetes, neurodegenerative diseases, cardiovascular and renal vascular diseases, and metabolic diseases.

[0174] Embodiment 86. Use of the lipid particle of any one of embodiments 36-61 or the pharmaceutical composition of any one of embodiments 62-63 in the preparation of a product for introducing a nucleic acid into a cell.

[0175] Embodiment 87. The use according to embodiment 86, wherein the product is for introducing a nucleic acid into a cell in vitro.

[0176] Embodiment 88. The use according to embodiment 86 or 87, wherein the cell is a mammalian cell.

[0177] The various embodiments described in the present disclosure (including the examples below) and the features in the various embodiments should be understood to be able to be arbitrarily combined with each other, and the various schemes obtained by these combinations are included in the scope of the present disclosure, just as the schemes obtained by these combinations are specifically and one by one listed in this document, unless the context clearly indicates otherwise.

[0178] Compositions and preparations

[0179] The pharmaceutical composition of the present disclosure may include the lipid nanoparticles of the present disclosure and a pharmaceutically acceptable excipient. The lipid nanoparticles include one or more different therapeutic and / or preventive agents. The pharmaceutical composition may further include one or more pharmaceutically acceptable excipients, such as those described herein. The pharmaceutically acceptable excipients include, but are not limited to, cryoprotectants, buffers, dispersants, wetting agents, suspending agents, or combinations thereof.

[0180] The pharmaceutical composition of the present disclosure can be prepared into various forms suitable for various routes and methods of administration. For example, the pharmaceutical composition can be prepared into liquid dosage forms (e.g., emulsions, microemulsions, nanoemulsions, solutions, suspensions, syrups and elixirs, such as sterile injectable aqueous or oily suspensions), solid dosage forms (e.g., capsules, tablets, pills, powders and granules), dosage forms for external use and / or transdermal administration (e.g., ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants and patches), powders and other forms.

[0181] Example

[0182] The following examples are illustrative of the present disclosure and are not intended to limit the present disclosure in any way. The data provided (e.g., amount, temperature, etc.) strive to ensure their accuracy, but those skilled in the art will appreciate that there will be some experimental errors and deviations. Unless otherwise stated, all temperatures are degrees Celsius and pressures are atmospheric pressure or near atmospheric pressure. All mass spectral data are measured by a triple quadrupole mass spectrometer. All nuclear magnetic resonance data are measured by a nuclear magnetic resonance spectrometer. Except for the synthetic intermediates, all reagents and raw materials used in the present disclosure are obtained from commercial channels.

[0183] In any structural formula herein, if there are vacant valencies on any atom, the vacant valencies are actually hydrogen atoms which are not specifically depicted for the sake of simplicity.

[0184] In this application, if both the name and the structural formula of a compound are given, in the event of inconsistency between the two, the structure of the compound shall prevail, unless the context indicates that the structure of the compound is incorrect and the name is correct.

[0185] The following is a list of abbreviations used in the examples:

[0186]

[0187]

[0188] Example

[0189] Example 1 Synthesis of Compound 1

[0190] Compound 1

[0191]

[0192] The synthetic route is as follows:

[0193]

[0194] Undecanol (1.36 g, 7.91 mmol), EDCl (1.52 g, 7.91 mmol), DMAP (0.13 g, 1.05 mmol) and DIEA (1.36 g, 10.52 mmol) were added to a solution of compound A (2.00 g, 5.26 mmol) in dichloromethane (30 ml), and the mixture was stirred at room temperature for 20 hours. The reaction was monitored by TLC. After the reaction was complete, purified water was added to the reaction solution and stirred, the mixture was separated, anhydrous sodium sulfate was added to the organic layer, the mixture was dried, filtered, the filtrate was concentrated, and the mixture was subjected to silica gel column chromatography (petroleum ether: ethyl acetate = 5:1) to obtain compound B (2.70 g, yield 96.09%).

[0195] Add TFA (5 ml) to a solution of compound B (2.50 g, 4.68 mmol) in dichloromethane (15 ml), stir at room temperature for 20 min, and monitor the reaction by TLC. After the reaction is complete, evaporate the solvent, add dichloromethane (30 ml) to the reaction solution, wash once with an equal volume of 5% sodium carbonate and purified water, add anhydrous sodium sulfate to dry the organic layer, filter, and concentrate the filtrate to obtain compound C (2.45 g).

[0196] Compound C (0.45 g, 1.04 mmol) in methanol (10 ml) was added with compound decyl acrylate (0.88 g, 4.16 mmol), stirred at 50°C for 16 hours, and the reaction was monitored by TLC. After the reaction was complete, distillation was performed, and silica gel column chromatography (dichloromethane: methanol = 60: 1) was used to obtain compound D (0.32 g, yield 47.76%).

[0197] Pd / C (64 mg) was added to a solution of compound D (0.32 g, 0.49 mmol) in methanol (5 ml), and stirred at room temperature for 16 hours under a hydrogen atmosphere. The reaction was monitored by TLC. After the reaction was complete, the mixture was filtered and the filtrate was distilled to obtain compound 1 (0.25 g); 1 H NMR (400MHz, CDCl3) δ4.21–4.11(m,4H),3.30–3.27(t,1H),3.01–2.95(m,1H),2.82–2.70(m ,3H),2.56–2.53(m,3H),1.84–1.66(m,10H),1.54–1.34(m,29H); MS-ESI(m / z):513.6(M+H) + .

[0198] Example 2 Synthesis of Compound 2

[0199] Compound 2

[0200]

[0201] The synthetic route is shown below.

[0202]

[0203] Add formaldehyde aqueous solution (0.35 g) to a solution of compound 1 (0.15 g, 0.29 mmol) in methanol / dichloromethane (2 ml / 2 ml), stir at room temperature for 0.5 h, add NaBH(OAc)3 (0.49 g, 2.32 mmol), stir at room temperature for 16 hours, and monitor the reaction by TLC. After the reaction is complete, add dilute hydrochloric acid to the reaction solution to quench the reaction, distill to remove the solvent, add dichloromethane and purified water, stir, separate the liquids, add anhydrous sodium sulfate to the organic layer, dry it, filter, concentrate the filtrate, and perform silica gel column chromatography (dichloromethane: methanol = 10: 1) to obtain compound 2 (0.13 g, yield 81.25%); 1 H NMR (400MHz, CDCl3) δ4.14–4.06(m,4H),3.27–3.23(t,1H),3.00–2.94(m,1H),2.86–2.79(m,1H),2.50–2.42(m,4H ),2.36–2.34(d,J=8.0Hz,9H),1.80–1.56(m,8H),1.41–1.30(m,29H),0.93–0.89(t,9H); MS-ESI(m / z):555.7(M+H) + .

[0204] Example 3 Synthesis of Compound 3

[0205] Compound 3

[0206]

[0207] The preparation method is the same as compound 1 and compound 2, and compound 3 can be prepared by using 6-hydroxyhexyl nonanoate instead of undecanol as the raw material; 1 H NMR (400MHz, CDCl3) δ4.16–4.10(m,6H),3.29–3.25(t,1H),3.02–2.95(m,1H),2.88–2.83(dd,J=14.0Hz,1H),2.70–2.66(t,2H),2.57–2.48(m ,8H),2.37–2.33(t,5H),2.05(s,1H),0.93–0.89(t,9H),1.75–1.65(m ,9H),1.44–1.33(t,20H),0.95–0.92(t,9H); MS-ESI(m / z):641.8(M+H) + .

[0208] Example 4 Synthesis of Compound 4

[0209] Compound 4

[0210]

[0211] The synthetic route is shown below.

[0212]

[0213] Add TBDMSCl (4.17 g, 27.70 mmol) and imidazole (3.43 g, 50.36 mmol) to a pyridine (40 ml) solution of compound L-threonine (3.00 g, 25.18 mmol), stir at room temperature for 24 hours, and monitor the reaction by TLC. After the reaction is complete, distill the solvent to remove it, add 50 ml of petroleum ether and 50 ml of purified water to the residue, slurry at room temperature, filter, wash the filter cake with petroleum ether and purified water, and dry it in vacuo to obtain compound E (3.52 g, yield 59.9%).

[0214] Add Boc anhydride (3.29 g, 15.08 mmol) and triethylamine (3.05 g, 30.16 mmol) to a solution of compound E (3.52 g, 15.08 mmol) in methanol / dichloromethane (20 ml / 20 ml), stir at room temperature for 7 h, and monitor the reaction by TLC. After the reaction is complete, evaporate the solvent, add dichloromethane (50 ml) to the reaction solution, wash twice with 1 mol / L hydrochloric acid, wash once with purified water, add anhydrous sodium sulfate to dry the organic layer, filter, and concentrate the filtrate to obtain compound F (5.40 g, yield 100.00%).

[0215] Undecanol (1.16 g, 6.75 mmol), EDCl (1.29 g, 6.75 mmol), DMAP (0.11 g, 0.90 mmol) and DIEA (1.16 g, 9.00 mmol) were added to a solution of compound F (1.50 g, 4.50 mmol) in dichloromethane (30 ml), and the mixture was stirred at room temperature for 15 hours. The reaction was monitored by TLC. After the reaction was complete, purified water was added to the reaction solution and stirred, and the mixture was separated. The organic layer was dried by adding anhydrous sodium sulfate, filtered, and the filtrate was concentrated and subjected to silica gel column chromatography (petroleum ether: ethyl acetate = 40: 1) to obtain compound G (1.33 g, yield 60.73%).

[0216] Trifluoroacetic acid (15 ml) was added to compound G (1.33 g, 2.73 mmol), and the mixture was stirred at room temperature for 4 hours. The reaction was monitored by TLC. After the reaction was complete, the solvent was evaporated, and dichloromethane (30 ml) was added to the reaction solution. The mixture was washed once with 5% sodium carbonate and purified water, respectively. The organic layer was dried with anhydrous sodium sulfate, filtered, and the filtrate was concentrated to obtain compound H (1.06 g, yield 100.00%).

[0217] TBAF / THF solution (5 ml) was added to a tetrahydrofuran (10 ml) solution of compound H (1.06 g, 2.73 mmol), and the mixture was stirred at room temperature for 18 hours under nitrogen protection. The reaction was monitored by TLC. After the reaction was complete, the solvent was evaporated and the mixture was purified by silica gel column chromatography (dichloromethane:

[0218] Methanol = 40:1) to give compound I (0.38 g, yield 50.67%).

[0219] To a solution of compound I (0.20 g, 0.73 mmol) in 1,2-dichloroethane (15 ml), acetic acid (0.2 ml) and compound J (0.43 g, 1.10 mmol) were added, and the mixture was stirred at 50°C for 1.0 h under nitrogen protection. NaBH(OAc)3 (0.46 g, 2.19 mmol) was added in batches and stirred at 50°C for 1 hour. The reaction was monitored by TLC. After the reaction was complete, the solvent was distilled off, and compound K (0.21 g, yield 43.75%) was obtained by silica gel column chromatography (dichloromethane: methanol = 60: 1);

[0220] To a solution of compound K (0.16 g, 0.24 mmol) in 1,2-dichloroethane (10 ml), acetic acid (0.2 ml) and compound L (68 mg, 0.24 mmol) were added, and the mixture was stirred at 50°C for 1.0 h under nitrogen protection. NaBH(OAc)3 (0.15 g, 0.72 mmol) was added in batches, and the mixture was stirred at 50°C for 1 hour. The reaction was monitored by TLC. After the reaction was complete, the solvent was distilled off, and compound 4 (0.12 g, yield 53.33%) was obtained by silica gel column chromatography (petroleum ether: ethyl acetate = 20:1); 1 H NMR (400MHz, CDCl3) δ4.92–4.89(t,1H),4.23–4.08(m,5H),3.91(s,1H),2.70–2.09(m,6H) ),1.69–1.47(m,18H),1.39–1.30(m,68H),0.94–0.90(t,12H); MS-ESI(m / z):922.8(M+H) + .

[0221] Example 5 Synthesis of Compound 5

[0222] Compound 5

[0223]

[0224] The preparation method is the same as compound 4, and compound 5 can be prepared by using compound J instead of compound L as the raw material; 1H NMR (400MHz, CDCl3) δ4.93–4.87 (m, 2H), 4.24–4.17 (t, 3H), 3.70–3.66 (dd, J = 10.0Hz, 1H), 2.69–2. 12(m,8H),1.63–1.53(m,15H),1.37–1.30(m,80H),0.94–0.90(t,18H); MS-ESI(m / z):1035.7(M+H) + .

[0225] Example 6 Synthesis of Compound 6

[0226] Compound 6

[0227]

[0228] The preparation method is the same as compound 4, and compound 6 can be prepared by using L-serine instead of L-threonine as the raw material; 1 H NMR (400MHz, CDCl3) δ4.92–4.89(t,1H),4.20–4.17(m,5H),3.78(s,1H),3.64–3.59(t,2H),2.64(s,3H),2.36–2.30(d d,J=16.0Hz,4H),2.09(s,1H),1.69–1.56(m,22H),1.35–1.31(m,58H),0.94–0.91(t,12H); MS-ESI(m / z):908.8(M+H) + .

[0229] Example 7 Synthesis of Compound 7

[0230] Compound 7

[0231]

[0232] The preparation method is the same as compound 5, and compound 7 can be prepared by using L-serine instead of L-threonine as the raw material; 1 H NMR (400MHz, CDCl3) δ4.93–4.87(m,2H),4.37–4.16(t,3H),3.57(s,1H),3.24(s,1H),2.63(s,2H),2.34–2.30(t,4H ),2.09(s,1H),1.87(s,1H),1.69–1.54(m,21H),1.38–1.30(m,74H),0.94–0.91(t,15H); MS-ESI(m / z):1020.9(M+H) + .

[0233] Example 8 Synthesis of Compound 8

[0234] Compound 8

[0235]

[0236] The synthetic route is shown below.

[0237]

[0238] Acetic anhydride (2.72 g, 26.66 mmol) was added dropwise to a NaOH aqueous solution (7 ml, 15%) of compound M (2.00 g, 7.11 mmol) under ice bath conditions, and stirred at room temperature for 0.5 h. The reaction was monitored by TLC. After the reaction was complete, pH was adjusted to 2-3 with dilute hydrochloric acid, ethyl acetate (30 ml) was added, and purified water (20 ml) was stirred. The organic phase was washed with purified water (10 ml), and anhydrous magnesium sulfate was added to the organic phase for drying, filtering, and distilling the organic phase to obtain a colorless oily compound N (2.32 g, yield 100.00%).

[0239] Undecanol (0.64 g, 3.71 mmol), EDCl (0.71 g, 3.71 mmol), DMAP (0.06 g, 0.49 mmol) and DIEA (0.64 g, 4.94 mmol) were added to a solution of compound N (0.80 g, 2.47 mmol) in dichloromethane (20 ml), and the mixture was stirred at room temperature for 20 hours. The reaction was monitored by TLC. After the reaction was complete, purified water was added to the reaction solution and stirred, the liquid was separated, anhydrous sodium sulfate was added to the organic layer, dried, filtered, the filtrate was concentrated, and silica gel column chromatography (methanol: dichloromethane = 20: 1) was used to obtain compound O (0.61 g, yield 51.69%).

[0240] Trifluoroacetic acid (5 ml) was added to a solution of compound O (0.61 g, 1.28 mmol) in dichloromethane (5 ml), and the mixture was stirred at room temperature for 0.5 h. The reaction was monitored by TLC. After the reaction was completed, the solvent was evaporated, and dichloromethane (30 ml) was added to the reaction solution. The mixture was washed once with 5% sodium carbonate and purified water, respectively. Anhydrous sodium sulfate was added to the organic layer for drying, and the mixture was filtered. The filtrate was concentrated and subjected to silica gel column chromatography (methanol: dichloromethane = 20:1) to give compound P (0.48 g, yield 68.57%).

[0241] To a solution of compound P (0.18 g, 0.48 mmol) in methanol (8 ml) was added compound deca-allylate (0.31 g, 1.44 mmol), the mixture was stirred at 50° C. for 25 hours under nitrogen protection, and distilled to obtain compound Q (0.72 g, yield 100.00%).

[0242] Ammonia water (2 ml) was added to a solution of compound Q (0.72 g, 0.48 mmol) in methanol (2 ml), and the mixture was stirred at room temperature for 24 hours. The reaction was monitored by TLC. After the reaction was complete, the solvent was evaporated and the compound R (0.25 g, yield 35.71%) was obtained by silica gel column chromatography (petroleum ether: ethyl acetate = 10:1).

[0243] To a solution of compound R (0.10 g, 0.19 mmol) in methanol (4 ml), acetic acid (0.4 ml) and compound L (0.27 g, 0.95 mmol) were added, nitrogen was protected, and the mixture was stirred at 50°C for 1.0 h. NaBH3CN (14 mg, 0.23 mmol) was added in batches and stirred at 50°C for 1.5 h. The reaction was monitored by TLC. After the reaction was complete, the solvent was distilled off, ethyl acetate (30 ml) and purified water (20 ml) were added, stirred, and the organic phase was washed with purified water (20 ml) again. The organic phase was distilled, and silica gel column chromatography (dichloromethane: methanol = 60: 1) was performed to obtain compound 8 (0.07 g, yield 45.75%). 1 H NMR(400MHz, CDCl3) δ7.10–7.07(d,J=12.0Hz,2H),6.78–6.76(d,J=8.0Hz,2H) ,4.97(s,1H),4.12–4.05(m,6H),3.56–3.52(t,1H),3.14–3.01(m,2H),2.84–2 .76(m,2H),2.62–2.54(m,2H),2.44–2.40(t,2H),2.30–2.25(t,2H),1.68–1.5 6(m,14H),1.36–1.30(m,42H),0.94–0.91(t,12H),;MS-ESI(m / z):816.9(M+H) + .

[0244] Example 9 Synthesis of Compound 9

[0245] Compound 9

[0246]

[0247] The synthetic route is shown below.

[0248]

[0249] To a solution of compound A-1 (6.00 g, 57.09 mmol) in dichloromethane (60 ml), tert-butyldimethylsilyl chloride (17.21 g, 114.18 mmol) was added, triethylamine (28 ml, 171.28 mmol) was slowly added dropwise, and stirred at room temperature for 20 hours. The reaction was monitored by TLC. After the reaction was complete, the reaction solution was concentrated and subjected to silica gel column chromatography (methanol: dichloromethane = 0-20%) to obtain compound B-1 (8.35 g, yield 66.71%).

[0250] Add Boc2O (5.01 g, 22.98 mmol) to a methanol (40 ml) solution of compound B-1 (4.20 g, 19.15 mmol), stir at room temperature for 16 hours, and monitor the reaction by TLC. After the reaction is complete, the reaction solution is concentrated and subjected to silica gel column chromatography (methanol: dichloromethane = 0-10%) to obtain compound C-1 (2.82 g, yield 46.13%).

[0251] Compound F-2 (1.18 g, 3.76 mmol), EDCl (0.90 g, 4.70 mmol), DMAP (0.01 g, 0.06 mmol) and DIEA (1 mL, 6.26 mmol) were added to a solution of compound C-1 (1.00 g, 3.31 mmol) in dichloromethane (10 ml), and the mixture was stirred at room temperature for 16 hours. The reaction was monitored by TLC. After the reaction was complete, ethyl acetate (20 ml) and water (20 ml) were added to the concentrate, and the extract was separated. The saturated brine organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and subjected to silica gel column chromatography (methanol: dichloromethane = 0-10%) to obtain compound D-1 (1.53 g, yield 79.43%).

[0252] TFA (5 mL) was added dropwise to a solution of compound D-1 (1.50 g, 3.13 mmol) in dichloromethane (15 ml). After the addition was completed, the mixture was stirred at room temperature for 5 hours and the reaction was monitored by TLC. After the reaction was complete, the reaction solution was concentrated, ethyl acetate (20 ml) and water (20 ml) were added to the concentrate, and the extract was separated. The saturated brine organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated and subjected to silica gel column chromatography (methanol: dichloromethane = 0-10%) to obtain compound E-1 (0.51 g, yield 52.15%).

[0253] Compound C-2 (0.28 g, 0.75 mmol) and DIEA (0.3 mL, 1.83 mmol) were added to a solution of compound E-1 (0.20 g, 0.50 mmol) in ethanol (2 ml), and the mixture was stirred at 70°C for 20 hours and the reaction was monitored by TLC. After the reaction was complete, the reaction solution was concentrated and subjected to silica gel column chromatography (methanol: dichloromethane = 0-10%) to obtain compound 1 (0.08 g, yield 23.01%). 1 H NMR(400MHz, CDCl3)δ4.22–4.17(m,2H),4.12–4.08(m,4H),3.85(dd,1H),3.70–3.61(m,1H),3.43–3.40(m,1H),2.79–2.73(m,1H), 2.62–2.55(m,1H),2.33(t,4H),1.72–1.54(m,10H),1.45–1.39(m,8H),1.37–1.25(m,20H),0.92(t,6H); MS-ESI(m / z):698.9(M+H) + .

[0254] Example 10 Synthesis of Compound 10

[0255] Compound 10

[0256]

[0257] The synthetic route is shown below.

[0258]

[0259] Compound G-3 (0.32 g, 0.75 mmol) and DIEA (0.3 mL, 1.83 mmol) were added to a solution of compound E-1 (0.20 g, 0.50 mmol) in ethanol (2 ml), and the mixture was stirred at 70°C for 20 hours and the reaction was monitored by TLC. After the reaction was complete, the reaction solution was concentrated and subjected to silica gel column chromatography (methanol: dichloromethane = 0-10%) to obtain compound 10 (0.06 g, yield 15.97%). 1H NMR (400MHz, CDCl3) δ4.93–4.87(m,1H),4.23–4.09(m,4H),3.85(dd,1H),3.71–3.62(m,1H),3.43–3.41(m,1H),2.81–2.74(m,1H), 2.63–2.54(m,1H),2.33(t,4H),1.72–1.64(m,8H),1.56–1.41(m,10H),1.38–1.25(m,50H),0.92(t,9H); MS-ESI(m / z):754.9(M+H) + .

[0260] Example 11 Synthesis of Compound 11

[0261] Compound 11

[0262]

[0263] The synthetic route is shown below.

[0264]

[0265] To a DCM solution (300 ml) of compound A-2 (40.60 g, 224.22 mmol) were added compound B-2 (24.02 g, 119.66 mmol), DIEA (36.02 g, 280.10 mmol), DMAP (2.70 g, 22.10 mmol), and EDCl (32.20 g, 167.97 mmol) in sequence at room temperature. The mixture was stirred at room temperature overnight and the reaction was monitored by TLC. After the reaction is complete, DCM is removed by concentration, ethyl acetate (200 ml) is added, purified water (300 ml) is stirred, the liquids are separated, the aqueous phase is extracted with ethyl acetate three times, each time with 150 ml, the organic phases are combined, washed once with purified water (500 ml) and once with saturated brine (500 ml), the organic phase is added with anhydrous sodium sulfate, dried, filtered, concentrated, and eluted with PE:EA=30:1 eluent to obtain an oily substance C-2 (23.92 g, yield 56.60%).

[0266] Compound B-2 (12.00 g, 55.98 mmol), DIEA (18.10 g, 140.05 mmol), DMAP (1.35 g, 11.05 mmol), EDCl (16.10 g, 83.99 mmol) were added to a DCM solution (130 ml) of compound D-2 (13.30 g, 112.55 mmol) in sequence at room temperature, and stirred overnight at room temperature. The reaction was monitored by TLC. After the reaction was complete, DCM was removed by concentration, ethyl acetate (150 ml) was added, and saturated sodium carbonate solution (150 ml) was stirred, and the liquid was separated. The organic phase was washed once with saturated brine (150 ml), and the organic phase was dried by adding anhydrous sodium sulfate, filtered, concentrated, and eluted with PE:EA=50:1 eluent to obtain oily F-2 (15.18 g, yield 71.91%).

[0267] Compound A-2 (4.21 g, 11.20 mmol), K2CO3 (3.78 g, 27.40 mmol), KI (1.60 g, 9.60 mmol), H2O (4 ml) were added to a DMF solution (40 ml) of compound G-2 (1.40 g, 9.00 mmol), and the mixture was heated to 80°C and stirred overnight. The reaction was monitored by TLC. After the reaction was complete, the mixture was cooled to room temperature, ethyl acetate (100 ml) was added, and water (100 ml) was added for extraction. The aqueous phase was extracted with ethyl acetate twice, each time with 100 ml, and the organic phases were combined and washed with purified water twice (200 ml each time) and saturated brine (210 ml) once. The organic phase was dried by adding anhydrous sodium sulfate, filtered, and concentrated. When the solvent was concentrated to 1 / 3, solid precipitated, and filtered to obtain white solid H-2 (1.11 g, yield 27.33%).

[0268] Compound F-2 (0.78 g, 2.48 mmol) and PTSA (1.14 g, 6.62 mmol) were added to a CHCl3 solution (26 ml) of compound H-2 (0.90 g, 1.99 mmol) in sequence, and the mixture was heated to reflux and stirred overnight. The reaction was monitored by TLC. When the remaining raw material was less, the mixture was cooled to room temperature, ethyl acetate (50 ml) was added, and water (50 ml) was used for extraction. The aqueous phase was extracted with ethyl acetate twice, each time with 50 ml, and the organic phases were combined and washed with purified water twice (each time with 150 ml). The organic phase was dried over anhydrous sodium sulfate, filtered, concentrated, and eluted with DCM:MeOH=20:1 eluent to obtain oily compound 8 (88.8 mg, yield 6.00%). 1HNMR(400MHz, CDCl3)δ7.53(s,1H),6.81(s,1H),4.13–4.00(m,6H),3.51(dd,J=7.7,5.0Hz,1H),3.07–2.79(m,2H),2.69–2.44(m,2H),2.28(t d,J=7.5,2.0Hz,4H),1.61(pt,J=7.0,3.3Hz,10H),1.49(p,J=6.2Hz,2H),1.36–1.22(m,44H),0.87(t,J=6.7Hz,6H).MS-ESI(m / z):748.9(M+H) +

[0269] Example 12 Synthesis of Compound 12

[0270] Compound 12

[0271]

[0272] The synthetic route is shown below:

[0273]

[0274] Compound B-3 (4.81 g, 18.61 mmol), DIEA (5.02 g, 38.84 mmol), DMAP (0.40 g, 3.27 mmol), EDCl (4.45 g, 23.21 mmol) were added to a DCM solution (70 ml) of compound A-3 (3.94 g, 15.43 mmol) in sequence at room temperature, stirred overnight at room temperature, and the reaction was monitored by TLC. After the reaction was complete, DCM was removed by concentration, ethyl acetate (100 ml) was added, purified water (90 ml) was stirred, and the liquid was separated. The aqueous phase was extracted with ethyl acetate twice, each time with an amount of 100 ml, the organic phases were combined, washed with purified water twice, each time with an amount of 250 ml, anhydrous sodium sulfate was added to the organic phase for drying, filtration, concentration, and elution with DCM: MeOH = 25: 1 eluent to obtain compound C-3 (3.32 g, yield 43.21%).

[0275] To a MeCN solution (50 ml) of compound C-3 (1.00 g, 2.01 mmol), bromoethanol (0.50 g, 4.00 mmol), Na2CO3 (1.30 g, 12.27 mmol), KI (0.70 g, 4.22 mmol) were added in sequence, the temperature was raised to 80°C, stirred overnight, and the reaction was monitored by TLC. After the raw material remained less, MeCN was removed by concentration, ethyl acetate (50 ml) was added, purified water (50 ml) was stirred, and the liquid was separated. The aqueous phase was extracted with ethyl acetate 3 times, each time with 50 ml, the organic phases were combined, washed once with purified water, the amount was 200 ml, anhydrous sodium sulfate was added to the organic phase for drying, filtration, concentration, and elution with EA:MeOH=20:1 eluent to obtain compound D-3 (0.32 g, yield 29.42%).

[0276] Trifluoroacetic acid (2 ml) was added to a DCM solution (4 ml) of compound D-3 (0.20 g, 0.37 mmol), stirred at rt for 0.5 h, and the reaction was monitored by TLC. After the reaction was complete, DCM and TFA were removed by concentration. DMF (5 ml), K2CO3 (0.16 g, 1.16 mmol), KI (0.06 g, 0.36 mmol), and compound G-3 (0.34 g, 0.74 mmol) were added to the obtained oily substance in sequence, and the temperature was raised to 80°C and stirred overnight. TLC monitoring revealed that there was less raw material remaining. The temperature was lowered to room temperature, ethyl acetate (50 ml) and water (50 ml) were added to the system, extracted, separated, and the organic phase was washed twice with purified water in an amount of 50 ml. The organic phase was dried by adding anhydrous sodium sulfate, filtered, concentrated, and eluted with DCM:MeOH=20:1 eluent to obtain compound 12 (68.00 mg, yield 22.43%). 1 HNMR (400MHz, CDCl3) δ7.44(d,J=1.3Hz,1H),6.81(d,J=1.3Hz,1H),4.89(p,J=6.3Hz,1H),4.11 (dt,J=17.4,6.7Hz,4H),4.03(t,J=5.0Hz,2H),3.88(t,J=5.0Hz,2H),3.66(dd,J=7.2,5.8Hz,1 H),3.06–2.83(m,2H),2.73–2.48(m,2H),2.31(dt,J=10.5,7.5Hz,4H),1.65(pd,J=7.3,3.6Hz, 8H),1.53(t,J=6.5Hz,8H),1.45–1.21(m,42H),0.92(t,J=6.7Hz,9H).MS-ESI(m / z):821.0(M+H) +

[0277] Example 13 Lipid Nanoparticle (LNP) Encapsulation

[0278] The mRNA stock solution was dispersed in a 20mM acetic acid solution (pH5.0) to a final concentration of 200μg / mL (referred to as the aqueous phase). The Example compound: cholesterol: DSPC: DMG-PEG2000 were mixed in a molar ratio of 50:38.5:10:1.5 to form a lipid mixture (referred to as the oil phase). The flow rates of the aqueous phase and the oil phase were controlled to mix the mRNA with the lipid mixture by T mixing to obtain the LNP-encapsulated mRNA. The encapsulated LNP was diluted with buffer, then concentrated by ultrafiltration, and the diluent was replaced. Finally, the LNP was concentrated to 200μg / mL of mRNA, and the pH of the LNP was adjusted to about 7-8. Finally, the Quant-iTRibogreen kit and 10% OTG were used as a demulsifier to detect the total content and free content of mRNA in the LNP, and the encapsulation rate of the LNP was calculated. The final LNP product was diluted with diluent, added to 1 ml of the particle size pool, and placed on the Malvern ZetaSizer instrument. The particle size and polydispersity index (PDI) of the LNP were measured using dynamic light scattering. The results are shown in Table 1.

[0279] Encapsulation efficiency is a key quality attribute of lipid particles. As can be seen from the table below, the test compounds all achieved an encapsulation efficiency suitable for delivery, especially compounds 1, 2, 3, 11 and 12 achieved significantly improved encapsulation efficiency, had a nanometer-scale particle size more suitable for mRNA delivery, and had a narrow PDI (all less than 0.3).

[0280] Table 1

[0281]

[0282]

[0283]

[0284] Example 14 Cell transfection efficiency

[0285] 1. Encapsulate the mRNA expressing Luciferase into different LNP formulations for later use, wherein the preparation method of LNP and the mRNA encapsulation method are as described in Example 13, and the cationic lipid compounds used in LNP are compounds 1-3 and compounds 9-12, respectively.

[0286] 2. Plate 293T cells into a 96-well cell culture plate with a cell density of 1×10*6 and culture at 37°C for 7 hours.

[0287] 3. Transfect 0.2 μg LNP-encapsulated Luciferase mRNA per well, transfect 3-6 wells per formulation, and incubate the plate in a 37°C carbon dioxide incubator for 24 hours.

[0288] 4. Lyse the cells, add Luci fluorescent substrate, and use Centro LB 963 microplate chemiluminescence instrument to quantify the fluorescence. The results are shown in Figure 1 .

[0289] Luciferase assay is the main method to test cell transfection efficiency by fluorescence intensity. Figure 1 The results (relative fluorescence intensity (RLU) on the vertical axis) show that the mRNA-LNP samples corresponding to the test compounds can all produce fluorescence, among which compound 9 has a significant difference compared with the blank control group (p<0.05), and compounds 10-12 have extremely significant differences compared with the blank control group (p<0.001), indicating that they have excellent transfection efficiency.

Claims

1. A compound of formula I, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: R1 and R2 are each independently a linear or branched C 6-22 Alkyl or C 6-22 alkenyl; R3 is H, straight or branched C 1-6 Alkyl, or -L3-G3-R3', wherein R3' is a linear or branched C 6-22 Alkyl or C 6-22 alkenyl; R4 is -C 1-6 Alkylene-NR'R", optionally substituted with 1 C 1-3 Alkyl-OH substituted imidazolyl, phenyl-OH or -OH, wherein R' and R" are each independently H or C 1-3 alkyl; R5 is H or a straight or branched C 1-6 alkyl; L1, L2 and L3 are each independently a linear or branched C 2-10 Alkylene; G1, G2 and G3 are each independently -O(C=O)- or -(C=O)O-; and n is 0 or 1.

2. The compound according to claim 1, its pharmaceutically acceptable salt or stereoisomer, wherein R2 is -CHRaRb, wherein Ra and Rb are each independently a linear C 6-12 alkyl; R3 is H; R4 is -OH; and R5 is H.

3. The compound according to claim 2, its pharmaceutically acceptable salt or stereoisomer, wherein Ra and Rb are each independently a linear C 6-8 alkyl.

4. A compound according to claim 1, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: R1 and R2 are each independently a linear or branched C 6-22 Alkyl or C 6-22 alkenyl; R3 is H or straight or branched C 1-6 alkyl; R4 is -C 1-6 Alkylene-NR'R" or optionally 1 C 1-3 Alkyl-OH substituted imidazolyl, wherein R' and R" are each independently H or C 1-3 alkyl; R5 is H; L1 and L2 are each independently a linear or branched C 2-10 Alkylene; G1 and G2 are each independently -O(C=O)- or -(C=O)O-; and n is 0 or 1.

5. The compound according to claim 1, its pharmaceutically acceptable salt or stereoisomer, wherein L1 and L2 are each independently a linear C 2-8 Alkylene, wherein the alkylene is optionally substituted with 1 or 2 methyl or ethyl groups.

6. The compound according to claim 5, its pharmaceutically acceptable salt or stereoisomer, wherein L1 and L2 are each independently a linear C 2-6 Alkylene, wherein the alkylene is optionally substituted with 1 or 2 methyl or ethyl groups.

7. The compound according to claim 1, its pharmaceutically acceptable salt or stereoisomer, wherein R1 is a linear or branched C 6-18 Alkyl; and R2 is a straight chain C 6-18 Alkyl, -(CH2) substituted with 1 or 2 methyl or ethyl groups 7-11-CH3, -CHRaRb or -CH2CHRaRb, wherein Ra and Rb are each independently a straight chain C 6-12 alkyl.

8. The compound according to claim 7, its pharmaceutically acceptable salt or stereoisomer, wherein R1 is a linear C 8-12 alkyl.

9. The compound according to claim 7, its pharmaceutically acceptable salt or stereoisomer, wherein Ra and Rb are each independently a linear C 6-8 alkyl.

10. The compound according to claim 1, its pharmaceutically acceptable salt or stereoisomer, wherein R3 is H, methyl or ethyl.

11. The compound according to claim 10, its pharmaceutically acceptable salt or stereoisomer, wherein R3 is H or methyl.

12. The compound according to claim 1, its pharmaceutically acceptable salt or stereoisomer, wherein R4 is -C 1-6 Alkylene-NR'R" or optionally 1 C 1-3 Alkyl-OH substituted imidazolyl, wherein R' and R" are each independently H or C 1-3 alkyl.

13. The compound according to claim 1, its pharmaceutically acceptable salt or stereoisomer, wherein R1 is a straight chain C 8-12 alkyl; R2 is a straight chain C 8-12 Alkyl, -(CH2) 6-10 -isopropyl or -CHRaRb, wherein Ra and Rb are each independently a straight chain C 7-10 alkyl; R3 is H or methyl; R4 is -(CH2)3-NR'R", wherein R' and R" are each independently H or methyl; R5 is H; L1 and L2 are each independently a linear C 2-6 Alkylene; G1 and G2 are each independently -O(C=O)- or -(C=O)O-; and n is 0 or 1.

14. The compound according to claim 1, its pharmaceutically acceptable salt or stereoisomer, wherein R4 is optionally replaced by 1 C 1-3 Imidazolyl substituted with alkyl-OH.

15. The compound according to claim 1, its pharmaceutically acceptable salt or stereoisomer, wherein R4 is 16. The compound according to claim 1, its pharmaceutically acceptable salt or stereoisomer, wherein the compound is selected from:

17. A lipid particle comprising a carrier and one or more therapeutic and / or preventive agents, wherein the carrier comprises a compound, a pharmaceutically acceptable salt or a stereoisomer thereof as described in any one of claims 1 to 16.

18. lipid particle according to claim 17, wherein the lipid particle is a lipid nanoparticle.

19. lipid granules according to claim 17, wherein said one or more treatments and / or preventive agents are nucleic acids.

20. lipid particles according to claim 19, wherein the nucleic acid is messenger RNA, short interfering RNA, asymmetric interfering RNA, RNA interference molecules, microRNA, antisense RNA, ribozyme, Dicer-substrate RNA, small hairpin RNA and mixtures thereof.

21. according to the lipid granule described in any one of claim 17-20, wherein said carrier also comprises phospholipid, steroid and PEG lipid, wherein: The phospholipids are selected from: 1,2-dilinoleoyl-sn-glycero-3-phosphocholine, 1,2-dimyristoyl-sn-glycero-phosphocholine, 1,2-dioleoyl-sn-glycero-3-phosphocholine, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine, 1,2-distearoyl-sn-glycero-3-phosphocholine, 1,2-di-undecanoyl-sn-glycero-phosphocholine, 1-palmitoyl-2-oleoyl-sn-glycero- 3-phosphocholine, 1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine, 1-oleoyl-2-cholesteryl hemisuccinyl-sn-glycero-3-phosphocholine, 1-hexadecyl-sn-glycero-3-phosphocholine, 1,2-dialinolenoyl-sn-glycero-3-phosphocholine, 1,2-diarachidonoyl-sn-glycero-3-phosphocholine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine, 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine, 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinolenoyl-sn-glycero-3-phosphoethanolamine, 1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine, 1,2-didocosahexaenoyl-sn - glycerol-3-phosphoethanolamine, 1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt, dipalmitoylphosphatidylglycerol, palmitoyloleoylphosphatidylethanolamine, distearoyl-phosphatidyl-ethanolamine, dipalmitoylphosphatidylethanolamine, dimyristoylphosphoethanolamine, 1-stearoyl-2-oleoyl-phosphatidylethanolamine, 1-stearoyl-2-oleoyl-phosphatidylcholine, sphingomyelin and mixtures thereof; wherein the steroid is selected from the group consisting of cholesterol, coprosterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, and mixtures thereof; and / or The PEG lipid is selected from: 1,2-dimyristoyl-sn-glyceromethoxypolyethylene glycol, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)], PEG-distearylglycerol, PEG-dipalmitoleyl, PEG-dioleyl, PEG-distearyl, PEG-diacyl glycinamide, PEG-dipalmitoylphosphatidylethanolamine or PEG-l,2-dimyristyloxypropyl-3-amine.

22. A pharmaceutical composition comprising the lipid particle of any one of claims 17-21 and a pharmaceutically acceptable excipient.

23. The pharmaceutical composition of claim 22 for use as a medicament.

24. The pharmaceutical composition of claim 22, for use in delivering a therapeutic and / or prophylactic agent to a subject.

25. The pharmaceutical composition of claim 22, for use in treating or preventing a disease or condition in a subject.

26. The pharmaceutical composition of claim 22, which is used for introducing a nucleic acid into a cell.

27. Use of the lipid particle described in any one of claims 17-21 or the pharmaceutical composition described in claim 22 in the preparation of a medicament for delivering a therapeutic and / or preventive agent to an individual.

28. Use of the lipid particle described in any one of claims 17-21 or the pharmaceutical composition of claim 22 in the preparation of a medicament for treating or preventing a disease or illness in an individual.

29. Use of the lipid particle described in any one of claims 17-21 or the pharmaceutical composition described in claim 22 in the preparation of a product for introducing nucleic acid into cells.